Soleo Health Selected by Novartis as Limited Drug Distribution Partner for Administration of LEQVIO®
Wednesday, July 27, 2022
Soleo Health, a national provider of complex specialty pharmacy services and an innovative leader in the field, has announced its selection as a limited distribution partner for LEQVIO®, a cardiovascular drug manufactured by Novartis, a leading global medicines company.
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require further reduction of low-density lipoprotein cholesterol (LDL-C).
Soleo Health will administer LEQVIO through subcutaneous injections to patients in the comfort of their own homes or at one of the company's Ambulatory Infusion Centers (AICs) located nationwide.
In addition to the administration of LEQVIO, Soleo Health will leverage its proprietary clinical outcomes program called SoleMetrics®. This program aims to collect and generate valuable real-world data over time for patients prescribed LEQVIO. By utilizing SoleMetrics, intelligent outcomes can be gathered from patients throughout their treatment journey with LEQVIO, providing clinical and economic value to key stakeholders.
Drew Walk, Chief Executive Officer of Soleo Health, highlighted the company's expertise in caring for patients with complex conditions and its ability to offer services in various settings of care. He stated, "We continue to expand our limited distribution partnerships with numerous drug manufacturers as they appreciate our dedication to clinical excellence and high-quality care."
Through this collaboration, Soleo Health reinforces its commitment to providing exceptional care to patients with complex healthcare needs and strengthening its position as a trusted partner for pharmaceutical manufacturers.